This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Companion Diagnostics Market, 2012-2023

NEW YORK, July 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Companion Diagnostics Market, 2012-2023 http://www.reportlinker.com/p01361266/Companion-Diagnostics-Market-2012-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

Targeted therapeutics and companion diagnostics are the pillars of personalised medicine. Personalised medicine is a genome-based therapeutic approach that aims to adopt customised treatment for each individual. It uses aspects of genetic testing for checking potential abnormalities and tailoring the treatment so as to make it as individualised as the disease itself.

Targeted drugs have been fast to overshadow the traditional drugs, which favour the concept of one-size-fits-all. This has primarily been due to their superior efficacy and safety profile. More recently, several targeted drugs are being developed in association with a companion diagnostic test, which aids the identification of target population most likely to benefit from the therapy. The biopharmaceutical industry has been sceptical and slow to adopt the concept of companion diagnostics, as it limits the target population for the drug. However, their use also allows the companies to command premium prices in the market for their targeted drugs. Several companion drugs have reached blockbuster status even after targeting a limited audience, including Herceptin and Glivec.

Both large and small biopharmaceutical companies are now actively developing drug-diagnostic combination products. The success of Herceptin and Glivec has proved that the benefits of use of companion diagnostics far outweigh the challenge of limited target population. In this report, we look at the extent of use of some popular companion diagnostic tests - Her-2/neu, KRAS, EGFR and c-kit - across some leading national markets.

The journey of a biomarker to a companion diagnostic is a long one, with the regulatory authorities favouring the co-development and approval of companion drug and diagnostic. Although complex, the pipeline for companion diagnostics is rich. In the future, the launch and success of drugs will also be governed by successful development of a commercial companion diagnostic test. The 2013-2023 period will see the launch of numerous new companion diagnostics. We have explored the opportunities for growth in this niche market for both pharmaceutical and diagnostic companies, presented case studies of some marketed drug-diagnostic combinations, analysed the rich pipeline and looked at the recent collaborations that will drive this market. Additionally, we have also analysed the current and future state of the molecular and tissue diagnostics market, to which all companion diagnostic tests belong.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs